ScholarIQanswers from OpenAlex
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
PaperCitations, authors & open-access status
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma have?
ScholarIQcitation count
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma has 237 citations in the OpenAlex counts ScholarIQ stores.
When was Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma published?
ScholarIQyear
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma has 2019 year in the ScholarIQ index.
What is the open-access status of Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma?
ScholarIQoa status
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma has bronze oa status in the ScholarIQ index.
What is the DOI of Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma?
ScholarIQdoi
The DOI for Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma is on the source record.
What is the PMID of Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma?
ScholarIQpmid
The PMID for Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma is on the source record.
What is the OpenAlex record for Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma?
ScholarIQopenalex
The OpenAlex for Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma is on the source record.